Picture loading failed.

Anti-F9;F10 therapeutic antibody (Pre-made Emicizumab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-177-1mg 1mg Inquiry
GMP-Bios-ab-177-10mg 10mg Inquiry
GMP-Bios-ab-177-100mg 100mg Inquiry
GMP-Bios-ab-177-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-F9;F10 therapeutic antibody (Pre-made Emicizumab biosimilar,Bispecific mAb)
INN Name Emicizumab
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4;G4
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesChugai Pharmaceutical;Roche
Conditions ApprovedHaemophilia A
Conditions Activena
Conditions Discontinuedna
Development Techna